胺碘酮治疗冠心病慢性心力衰竭并室性期前收缩的临床疗效

Clinical efficacy of amiodarone in the treatment of coronary heart disease with chronic heart failure and ventricular premature contractility

目的:探讨胺碘酮治疗冠心病慢性心力衰竭并室性期前收缩的临床疗效。方法:选取126例冠心病慢性心力衰竭并室性期前收缩患者,随机分为观察组和对照组,对照组患者进行常规治疗,观察组患者在对照组患者治疗基础上加用胺碘酮治疗,比较两组患者临床疗效,治疗前、后心功能指标及不良反应发生情况。结果:观察组患者的治疗总有效率高于对照组(P<0.05),治疗后观察组患者左心室舒张末期内径((left ventricular end diastolic diameter,LEVDD)、左心室收缩末期内径(left ventricular end systolic diameter,LVESD)及室性期前收缩总数低于对照组患者(P<0.05),左心室射血分数(left ventricular ejection fractions,LVEF)高于对照组患者(P<0.05),观察组患者的不良反应发生率低于对照组(P<0.05)。结论:胺碘酮治疗冠心病慢性心力衰竭并室性期前收缩患者临床疗效好,对患者的心功能起到改善作用,不良反应少,具有较高安全性,值得推广。

Objective： To explore the clinical efficacy of amiodarone in the treatment of coronary heart disease （CHD） with chronic heart failure and ventricular premature contractility. Methods ：126 eases of CHD patients with chronic heart failure and ventricular premature contract were selected and randomly divided into ob- servation group and control group. The patients in control group were treated with conventional therapy and those in observation group received amiodarone on the basis of the treatment in control group. The clinical efficacy, cardiac function before and after treatment and adverse reactions in the two groups were compared. Results： The total effective rate in observation group was significantly higher than that in control group （ P 〈 0.05）. After the treatment, the left ventricalar end diastolic diam- eter （LVEDD）, left ventricular end systolic diameter （LVESD） and ventricular premature contraction （VPC） in observation group were lower than those in control group （ P 〈 0.05 ）. The left ventricular ejection fractions （LVEF） in observation group was higher than that in control group （ P 〈 0.05 ）. The incidence of adverse reactions in observation group was significantly lower than that in control group （ P 〈 0.05）. Conelusion：Amiodarone has a significant clinical efficacy in CHD pa- tients with chronic heart failure and ventricular premature ventricular contraction, and can improve their cardiac function, with less incidence of adverse reactions and high safety, which is worthy of promotion.